icon
icon
icon
icon
Upgrade
icon

Upstream Bio (UPB.US) IPO priced at $15-$17/share, raising $200M

AInvestTuesday, Oct 8, 2024 3:11 am ET
1min read

Upstream Bio, a clinical-stage biotechnology company, announced IPO terms Monday, planning to sell 12.5 million shares at $15 to $17 each, raising $200 million.

The company expects to price this week. At the midpoint of the proposed range, it will have a fully diluted market capitalization of $850.7 million.

Upstream Bio is a clinical-stage biotechnology company developing monoclonal antibodies for respiratory diseases. Its lead candidate is Verekitug, a monoclonal antibody for the treatment of severe respiratory diseases. Verekitug is designed to target and inhibit the thymic stromal lymphopoietin receptor, which Upstream Bio has advanced to a Phase 2 clinical trial for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps. The company also plans to include it in a Phase 2 clinical trial for chronic obstructive pulmonary disease.

Upstream Bio was founded in 2021 and had $2 million in sales over the 12 months ended June 30, 2024. It plans to list on the Nasdaq under the symbol UPB. Joint bookrunners on the deal are J.P. Morgan, TD Cowen, Piper Sandler and William Blair.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.